Download PDF
Thromb Haemost 2006; 96(02): 236-237
DOI: 10.1160/TH06-06-0295
Letter to the Editor
Schattauer GmbH

TAFI activity in coronary artery disease: A contribution to the current discussion on TAFI assays

Verena Schroeder
1   Laboratory for Thrombosis Research, Department of Clinical Research, Inselspital, University Hospital, Bern, Switzerland
,
Marianne Wilmer
2   Pentapharm Ltd, Basel, Switzerland
,
Beatrice Buehler
2   Pentapharm Ltd, Basel, Switzerland
,
Hans P. Kohler
1   Laboratory for Thrombosis Research, Department of Clinical Research, Inselspital, University Hospital, Bern, Switzerland
› Author Affiliations
Further Information

Publication History

Received 01 June 2006

Accepted after resubmission 07 July 2006

Publication Date:
28 November 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 Nesheim ME. TAFI. Review. Fibrinol Proteol 1999; 13: 72-7.
    CrossrefPubMedSearch in Google Scholar
  • 2 Wang W, Boffa MB, Bajzar L. et al. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998; 273: 27176-81.
    CrossrefPubMedSearch in Google Scholar
  • 3 Leurs J, Hendriks D. CarboxypeptidaseU (TAFIa): a metallocarboxypeptidase with a distinct role in haemostasis and a possible risk factor for thrombotic disease. Thromb Haemost 2005; 94: 471-87.
    Thieme ConnectPubMedSearch in Google Scholar
  • 4 Gils A, Alessi MC, Brouwers E. et al. Development of a genotype 325-specific proCPU/TAFI ELISA. Arterioscler Thromb Vasc Biol 2003; 23: 1122-7.
    CrossrefPubMedSearch in Google Scholar
  • 5 Guimaraes AHC, van Tilburg NH, Vos HL. et al. Association between thrombin activatable fibrinolysis inhibitor genotype and levels in plasma: comparison of different assays. Br J Haematol 2004; 124: 659-65.
    CrossrefPubMedSearch in Google Scholar
  • 6 Verdú J, Marco P, Benlloch S. et al. Thrombin activatable fibrinolysis inhibitor (TAFI) polymorphisms and plasma TAFI levels measured with an ELISA insensitive to isoforms in patients with venous thromboembolic disease (VTD). Thromb Haemost 2006; 95: 585-6.
    Thieme ConnectPubMedSearch in Google Scholar
  • 7 Schroeder V, Chatterjee T, Mehta H. et al. Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by angiography. Thromb Haemost 2002; 88: 1020-5.
    Thieme ConnectPubMedSearch in Google Scholar